What Is Eucrisa (crisaborole)?

Topical phosphodiesterase-4 (PDE4) inhibitors are prescription medications applied to the skin that interact with the immune response. The U.S. Food and Drug Administration (FDA) has approved one topical PDE4 inhibitor for the treatment of mild to moderate atopic dermatitis (AD), Eucrisa™ (crisaborole).1

Eucrisa is a topical treatment for mild to moderate AD in individuals 3 months of age and older.4 The active ingredient in Eucrisca is crisaborole (2%).1

How does Eucrisa work?

While the exact mechanism of action of Eucrisa in atopic dermatitis is not well understood, topical PDE4 inhibitors increase the levels of a chemical messenger called cyclic adenosine monophosphate (cAMP).1,2 The increase of cAMP in your body then suppresses the release of proteins called cytokines that cause inflammation which can lead to atopic dermatitis.5,6

In people with AD, the immune response is dysfunctional, resulting in an increased level of inflammation in the skin. By increasing cAMP levels and interrupting the immune response of inflammation, topical PDE4 inhibitors like Eucrisa can reduce the symptoms of AD like redness, oozing, crusting, and papules (bumps).1

Things to know about Eucrisa

People who have a known allergy or hypersensitivity reaction to crisaborole should not use Eucrisa. Eucrisa has not been studied for its safety in pregnant women or in women who are breastfeeding.

Women who are pregnant, plan to become pregnant, or who are breastfeeding should talk to their doctor about the risks and benefits of using Eucrisa. Eucrisa is for external use only and should not be used in the eyes, mouth, or vagina.

Dosing for Eucrisa

Eucrisa ointment contains 2% crisaborole. A thin layer of ointment is applied to the areas of skin affected by AD twice daily.

What are the possible side effects of Eucrisa?

The most common side effect experienced by people using Eucrisa in clinical trials was pain at the application site, such as burning or stinging.

Rarely, hypersensitivity reactions have occurred in people using Eucrisa, including contact urticaria. Contact urticaria is an immediate, localized hypersensitivity reaction that occurs on the skin and usually clears within a few hours. If a hypersensitivity reaction occurs, with symptoms including severe itching, redness, and swelling at the application site or at a distant site, the use of Eucrisa should be discontinued immediately. Additional medical attention may be needed.1,3

These are not all the possible side effects of Eucrisa. Patients should talk to their doctor about what to expect with treatment with Eucrisa.

For additional information on Eucrisa, read the full prescribing information.

By providing your email address, you are agreeing to our privacy policy. We never sell or share your email address.

Written by Emily Downward | Reviewed June 2021